Cagrilintide for appetite control: what the trials actually show

What's this video probably claiming?

Based on the caption and hashtag context, @olympuspeptidosmx is almost certainly positioning cagrilintide as a superior or next-level appetite suppressant, likely framing it as the answer for people who aren't getting enough hunger control from GLP-1s alone. The phrase "CONTROL real del apetito" signals a pitch around satiety mechanisms that go beyond what semaglutide or tirzepatide offer on their own. Given the account appears to be a Mexican peptide vendor, the video probably presents cagrilintide as something you can acquire and use now, possibly as a standalone or stacked compound. That framing deserves serious scrutiny, because cagrilintide is not approved anywhere as a standalone therapy, and the most relevant data comes from it being studied in combination with semaglutide (the combo called CagriSema) in Novo Nordisk's trial pipeline. Presenting it as a ready solution ignores where the science actually sits.

What does the science actually show?

Cagrilintide is a long-acting amylin analogue. Amylin is a peptide co-secreted with insulin from pancreatic beta cells that slows gastric emptying and signals satiety to the hypothalamus. The rationale for combining it with a GLP-1 receptor agonist is mechanistically sound: two different satiety pathways hit simultaneously. The Phase 2 SCALE data for cagrilintide alone (Enebo et al., 2021, The Lancet) showed dose-dependent weight loss of up to 10.8% body weight over 26 weeks at the 4.5 mg dose in people with obesity, which is meaningful but not dramatic compared to semaglutide 2.4 mg achieving roughly 15% in STEP 1 (Wilding et al., 2021, NEJM). The real excitement is the CagriSema combination. A Phase 2 trial (Frias et al., 2023, The Lancet) showed up to 15.6% weight loss at 20 weeks, and Phase 3 REDEFINE trials are ongoing. The standalone amylin signal is real. The combined signal is promising but unfinished.

Where does the social media noise diverge from clinical reality?

The gap here is significant. Peptide vendor accounts routinely compress years of trial work into a caption implying the compound is proven, available, and safe to self-administer. Cagrilintide has no regulatory approval anywhere as of mid-2025. The doses studied in Enebo et al. were administered under clinical supervision with careful titration from 0.3 mg up to 4.5 mg over multiple weeks, and nausea was reported in over 30% of participants even in controlled settings. Compounded or gray-market cagrilintide has no verified purity, potency standardization, or sterility guarantee, and there is zero published data on what happens when people stack it with tirzepatide or other compounds outside of a protocol. The hashtag pairing with tirzepatida specifically implies a stack, which is not studied in any published trial. Claiming this combination offers "real" appetite control while omitting that it's untested in free-living, self-dosing populations is a meaningful omission, not a minor caveat.

What should you actually know?

Cagrilintide has a legitimate scientific basis and a real trial record. The amylin pathway is not hype. But legitimate science and vendor-ready availability are two completely different things, and conflating them is how people get hurt. If you are genuinely interested in where cagrilintide is heading, watch the REDEFINE 1 and REDEFINE 2 Phase 3 readouts from Novo Nordisk, which are expected to report in 2025 and 2026. Those will tell us whether the Phase 2 signal holds in a larger, longer, more diverse population. What you should not do is source a peptide from a social media vendor, attempt to replicate a clinical titration schedule from a caption, or assume that combining unapproved compounds is equivalent to the studied CagriSema protocol. The pharmacology is interesting. The vendor context is not the right place to act on it.